Aster DM's profit barely grows as costs and finance charges offset revenue surge
Revenue growth accelerated, but a 3.79-percentage-point margin decline and a 217.92% rise in interest expense kept net profit growth to 1.47% YoY.
Filed 06 Nov 2026, 16:56 IST · after market close · Aster DM Quality Care Ltd (ASTERDM)
Key takeaways
- Standalone revenue rose 76.62% YoY, but expenses grew 85.20%, narrowing operating margin by 3.79 percentage points to 18.18%.
- Net profit increased only 1.47% YoY as interest expense jumped 217.92%, while the tax rate fell 15.85 percentage points.
- Operating margin was 3.52 percentage points below the 21.70% median for 83 healthcare peers that had reported.
Price around the results
Revenue growth did not translate into operating leverage
This was a standalone quarter with revenue growth of 76.62% YoY, but expenses grew faster at 85.20%, cutting operating margin by 3.79 percentage points to 18.18%. Sequentially, revenue rose 65.93% while expenses increased 70.25%, narrowing margin by a further 2.07 percentage points. Management said emerging units grew 62% YoY, while occupancy rose from 65% to 68% on higher patient volumes and MVT flows.
Interest costs and tax effects shaped reported profit
Operating profit grew 46.13% YoY, but interest expense rose 217.92% and depreciation increased 71.86%, leaving net profit up only 1.47%. Other income accounted for 28.49% of pre-tax profit, so reported earnings also had a material non-operating contribution. The 5.16% tax rate, down 15.85 percentage points YoY and 226.15 percentage points sequentially, further supported net profit.
Margin remains below peers after a mixed quarterly trend
Aster DM's 18.18% operating margin was 3.52 percentage points below the 21.70% median among 83 healthcare peers that had reported. The margin has moved from 21.97% in Q2FY26 to 19.33% in Q3FY26, 21.12% in Q4FY26, 20.25% in Q1FY27 and 18.18% in Q2FY27, so the latest decline follows a brief recovery rather than a continuous fall.
Capacity and clinical investments remain the management focus
Management said it plans to add 4,230 beds, taking total capacity to over 15,000. The company said it commissioned a 32-bed CARE Cancer Institute in Raipur and added one LINAC, one Digital PET-CT, three robots, two cath labs and one MRI during the quarter. It also said it invested more than Rs 600 cr in medical technology over the last 18 months.
No immediate market reaction after the post-close filing
After the previous eight results, the stock rose seven times and fell once, with a median absolute move of 3.27%.
Q2FY27 at a glance
Standalone figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q2FY27 | Q1FY27 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹1,204 cr | ₹726 cr | +65.93% | +76.62% |
| Other income | ₹32 cr | ₹-71 cr | — | -27.98% |
| Expenses | ₹985 cr | ₹579 cr | +70.25% | +85.20% |
| Operating profit | ₹219 cr | ₹147 cr | +48.94% | +46.13% |
| Operating margin (%) | 18.18% | 20.25% | — | — |
| Interest | ₹72 cr | ₹24 cr | +198.33% | +217.92% |
| Depreciation | ₹67 cr | ₹41 cr | +62.71% | +71.86% |
| Profit before tax | ₹112 cr | ₹11 cr | +927.73% | -15.49% |
| Tax | ₹6 cr | ₹25 cr | -77.09% | -79.26% |
| Net profit | ₹106 cr | ₹-14 cr | — | +1.47% |
| EPS (₹) | ₹1.29 | ₹-0.28 | — | -36.76% |
Operating margin of 18.18% compares with a Healthcare sector median of 21.70% across 83 peers that have reported Q2FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- Emerging units grew 62% year on year, supported by higher inpatient and outpatient volumes.
- Occupancy increased by 335 basis points from 65% to 68%, led by patient volume growth and higher MVT patient flows.
Guidance & outlook
- The company plans to add 4,230 beds, taking total bed capacity to over 15,000.
Expansion
- The company commissioned a 32-bed CARE Cancer Institute in Raipur to expand advanced cancer care in Chhattisgarh.
- The company added one LINAC, one Digital PET-CT, three robots, two cath labs and one MRI in Q2 FY27.
- The company invested more than INR 600 crore in medical technology over the last 18 months.
- The company lists planned bed additions of 1,179, 1,941 and 1,110 across the three regions.
New initiatives
- The company launched the Robotic Spine Institute at Aster CMI, Bengaluru.
- The company launched a deceased-donor transplant programme and comprehensive stroke unit at KIMSHEALTH Nagercoil.
- The company launched and scaled the Da Vinci robotic surgery programme to 72 cases at KIMSHEALTH Trivandrum.
What to watch
- Whether operating margin recovers from 18.18% toward the 21.70% healthcare-peer median.
- Whether interest expense growth moderates after rising 217.92% YoY.
- Whether occupancy remains at or above the reported 68% level.